CBD Properties. What is CBD? The Complete Guide 2026
CBD - properties, effects, legality in Poland 2026. Formula C21H30O2, ECS mechanism, oils and herbs. WHO has deemed CBD safe in doses up to 1500 mg (WHO, 2018).
What is CBD? More and more Poles are asking this question, and the market is responding with momentum. The global cannabidiol market value exceeded $7.7 billion in 2023, and the CAGR forecast through 2030 is 12.31 TP3T (Fortune Business Insights, 2024). CBD (cannabidiol) is the second most abundant cannabinoid in Cannabis sativa L. after THC, but it differs from it in one key feature: it does not cause psychoactive effects.
CBD's comprehensive properties include anxiolytic, anti-inflammatory, anticonvulsant, and neuroprotective effects. The World Health Organization confirmed cannabidiol's good safety profile and lack of addictive potential in a 2018 review (WHO, 2018). A year earlier, the FDA approved Epidiolex, the first CBD-only drug, for the treatment of refractory epilepsy in children.
In this guide, we discuss CBD from the molecular level (formula C21H30O2, 21 carbon atoms) to its practical applications. You'll learn about its mechanism of action on the endocannabinoid system, the differences between CBD and THC, extraction methods (supercritical CO2 vs. ethanol), legal status in Poland in 2026, and available product forms. The material is based on research from PubMed, PMC, Nature, and clinical publications from the last six years.
KEY INFORMATION
– CBD is cannabidiol, a compound with the formula C21H30O2 from Cannabis sativa L., without psychoactive properties (PMC, Frontiers in Pharmacology, 2020).
– It works by modulating the ECS, 5-HT1A, TRPV1, PPAR-gamma and GPR55 receptors, without binding strongly to CB1.
– WHO (2018) confirmed the good safety profile of CBD at doses up to 1500 mg per day in humans.
– In Poland, CBD is legal without a prescription, provided that the product contains less than 0.3% THC in the dried product.
– The FDA approved Epidiolex (pure CBD) in 2018 for the treatment of Dravet and Lennox-Gastaut syndromes.
What is CBD – definition and chemical structure
CBD (cannabidiol) is a phytocannabinoid with the molecular formula C21H30O2, consisting of 21 carbon atoms, 30 hydrogen atoms, and 2 oxygen atoms. The molar mass is 314.46 g/mol (PubChem, NCBI, 2024). Cannabidiol is the second most concentrated cannabinoid in cannabis, after THC. In fiber varieties, it typically accounts for 10-20% of the flower weight.
CBD's structure is derived from cannabidiolic acid (CBDA), which in turn is derived from the universal precursor cannabigerolic acid (CBGA). Decarboxylation, induced by heat or time, converts CBDA into the active form of CBD. The molecule contains two aromatic rings and a pentyl chain, crucial for receptor binding.
CBD was discovered in 1940 at the University of Illinois, but its full structure wasn't deciphered until 1963 by Israeli chemist Rafael Mechoulam. The same team identified THC a year later. The difference in the effects of the two compounds, despite their identical atomic composition, became a key research topic for the next 60 years.
Origin in the Cannabis sativa plant
CBD occurs naturally in Cannabis sativa L., or hemp. The highest concentrations are found in trichomes, the resin glands on female inflorescences. In fibrous varieties (hemp), CBD content ranges from 5% to 25% dry weight. In indica varieties (marijuana), other cannabinoids predominate, primarily THC.
Fiber varieties must meet the 0.31 TP3T THC limit in dried material, in accordance with European and Polish law. Higher CBD varieties are the result of selective breeding conducted since the 1990s. Charlotte's Web, ACDC, and Harlequin are examples of genetic lines optimized for high CBD content with minimal THC.
CBD vs THC – Structural Differences
CBD and THC have the same molecular formula, C21H30O2, but different molecular geometry. THC has a closed ring, which allows for strong binding to the CB1 receptor in the brain. CBD remains an open cyclic structure, does not bind to CB1, and does not produce psychoactive effects (PMC, Frontiers in Pharmacology, 2020).
This subtle spatial difference explains the dramatically different effects of the two cannabinoids. THC activates CB1, leading to altered perception, euphoria, and short-term memory impairment. CBD, on the other hand, modulates CB1 allosterically. This means that it doesn't "switch on" the receptor but alters its response to other molecules, including THC itself.
Citation capsule: CBD and THC have an identical chemical formula (C21H30O2), but a different three-dimensional structure. CBD does not bind strongly to the CB1 receptor in the brain, so it does not produce psychoactive effects, unlike THC (PMC, Frontiers in Pharmacology, 2020). This is a key difference that determines the legal status and use profile of both cannabinoids.
How CBD affects the body – molecular mechanism
CBD works multi-directionally, engaging at least eight different molecular targets in the body. Its primary field of activity is the endocannabinoid system (ECS), but cannabidiol also modulates serotonin 5-HT1A, vanilloid TRPV1, nuclear PPAR-gamma, and orphan GPR55 receptors (PMC, Frontiers in Pharmacology, 2020). This multifaceted approach explains the wide spectrum of therapeutic effects.
Unlike traditional drugs that target a single receptor, CBD is an example of "multitarget pharmacology." This isn't a disadvantage, but an advantage—it allows for subtle tuning of multiple body systems simultaneously. Therefore, CBD's effects appear gradually, after 2-4 weeks of regular use, rather than immediately as with traditional medications.
The Endocannabinoid System (ECS) – A Key Player
The endocannabinoid system (ECS) was only discovered in the 1990s. It consists of three components: endogenous cannabinoids (anandamide, 2-AG), cannabinoid receptors (CB1, CB2), and metabolizing enzymes (FAAH, MAGL). The ECS regulates sleep, appetite, pain, mood, immunity, memory, and internal homeostasis throughout the body.
CBD does not bind strongly to CB1 or CB2. Instead, it acts as a negative allosteric modulator of CB1. This means it alters how the receptor responds to other cannabinoids, including its own endogenous cannabinoids. This indirect effect explains CBD's lack of psychoactivity, despite its influence on the cannabinoid-dependent system.
The second important mechanism is the inhibition of the FAAH enzyme (fatty acid amidohydrolase). FAAH breaks down anandamide, an endogenous cannabinoid known as the "happiness molecule." By blocking FAAH, CBD increases natural anandamide levels. This is one explanation for its anti-anxiety and mood-enhancing effects.
5-HT1A, TRPV1, PPAR-gamma and GPR55 receptors
The 5-HT1A receptor is the target of many antidepressants (e.g., buspirone). CBD activates 5-HT1A, which translates into anxiolytic and antidepressant effects. In an animal model, CBD demonstrated an effect comparable to imipramine, a classic antidepressant (PubMed, 2010).
TRPV1 is a vanilloid receptor known for its response to capsaicin in hot peppers. It is crucial for pain and heat perception. CBD activates TRPV1, which leads to desensitization—the initial stimulation and subsequent extinction of the pain signal. This explains cannabidiol's analgesic effects, especially in neuropathic pain.
PPAR-gamma is a nuclear receptor that regulates metabolism and inflammation. CBD is an agonist, which explains its anti-inflammatory and neuroprotective effects. GPR55, sometimes called the "third cannabinoid receptor," is antagonistically modulated by CBD, which is important in modulating pain and bone function.
Unique observation: CBD acts a bit like an orchestral conductor, not a soloist. It doesn't "order" a single receptor to act in a specific way, but subtly coordinates the work of multiple systems simultaneously. This is why users often describe CBD's effects as "I feel more like myself" rather than "I feel different." This subtle regulation of homeostasis explains why CBD doesn't induce classic tolerance or addiction.
Citation capsule: CBD is an allosteric modulator of the CB1 receptor and activates 5-HT1A, TRPV1, PPAR-gamma, and GPR55 receptors. Additionally, it inhibits the FAAH enzyme, increasing endogenous anandamide levels. This multi-modality of action explains its broad spectrum of therapeutic effects without psychoactive effects (PMC, Frontiers in Pharmacology, 2020).
What are the properties of CBD confirmed by research?
CBD's properties encompass five main pharmacological areas: anxiolytic, anti-inflammatory, anticonvulsant, neuroprotective, and antioxidant effects. All of these effects have been confirmed in preclinical studies, and some in randomized clinical trials in humans (PMC, Frontiers in Pharmacology, 2020). The most well-documented is its anticonvulsant effect.
In 2018, the FDA approved Epidiolex, a standardized 100 mg/ml oral CBD solution, for the treatment of refractory childhood epilepsy syndromes (Dravet and Lennox-Gastaut). It was the first cannabinoid preparation ever approved by the US drug agency. A year later, the EMA approved it in Europe under the name Epidyolex.
Anxiolytic (anti-anxiety) action
CBD reduces social anxiety, generalized anxiety disorder, and PTSD symptoms. A 2019 randomized trial of 57 men with social anxiety disorder found that a single dose of 300 mg of CBD significantly reduced public speaking anxiety, as measured by the VAMS and SSPS-N (PubMed, Brazilian Journal of Psychiatry, 2019). Doses of 150 mg and 600 mg were less effective.
CBD's anti-anxiety effect is primarily due to activation of the 5-HT1A receptor. It works similarly to buspirone, but without the latter's typical "lag time." A 2023 clinical trial in 67 patients showed 52% reduced anxiety after 8 weeks of supplementing with 25-50 mg of CBD daily (Medical Cannabis and Cannabinoids, 2023).
Anti-inflammatory and immunomodulatory effects
CBD inhibits the production of proinflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and immune cell migration. This mechanism involves activation of PPAR-gamma, the CB2 receptor on immune cells, and direct modulation of the NF-kB pathway. A 2020 review of studies shows a reduction in CRP and inflammatory markers in patients with arthritis.
In clinical practice, CBD is being studied in inflammatory bowel disease (IBD, Crohn's disease), rheumatoid arthritis, and autoimmune skin diseases (psoriasis, atopic dermatitis). The topical action of CBD creams and ointments has been well demonstrated in acne vulgaris by inhibiting sebocytes.
Anticonvulsant effect
This is the most documented effect of CBD. In a Phase 3 clinical trial, CBD reduced the number of seizures by 39% in children with Dravet syndrome, compared with 13% in the placebo group (New England Journal of Medicine, 2017). It was this data that led to the FDA's registration of Epidiolex in 2018.
The anticonvulsant mechanism is multi-level. CBD modulates sodium and calcium channels, antagonizes GPR55, and activates PPAR-gamma. The effect is so potent that CBD has become the first-line treatment for some refractory childhood epilepsies. In adults with epilepsy, the results are less clear but promising.
Neuroprotective and antioxidant effects
CBD protects neurons from oxidative stress, glutamate toxicity, and neurodegeneration. CBD's antioxidant power surpasses that of vitamins C and E in in vitro tests. Therefore, cannabidiol is being studied in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and brain trauma (PubMed, 2011).
In an animal model of Alzheimer's disease, CBD reduced beta-amyloid protein aggregation and reduced neuroinflammation. Human studies are in the early stages, but the trend is very promising. Neuroprotective effects also apply to multiple sclerosis, where CBD is a component of the drug Sativex (CBD + THC 1:1).
How CBD is obtained – extraction methods
CBD is extracted from hemp biomass primarily using two methods: supercritical carbon dioxide (CO2) extraction and ethanol extraction. Lipid solvents (oil, butter) are less commonly used in home production. The supercritical CO2 method is considered the gold standard due to the purity of the final product (PubMed, 2019).
The quality of CBD oil depends largely on the extraction method. The terpene profile, chlorophyll content, and contaminant content (pesticides, heavy metals, residual solvents) vary depending on the process. Reputable producers publish a Certificate of Analysis (COA) for each batch, allowing consumers to verify the composition.
Supercritical CO2 extraction
Supercritical CO2 extraction uses carbon dioxide in a state between gas and liquid, achieved at approximately 74 bar pressure and 31°C. In this state, the CO2 dissolves lipophilic cannabinoids and terpenes without thermally damaging them. After decompression, the CO2 evaporates, leaving a pure cannabinoid concentrate in the extract.
Advantages of this method: no solvent residue, preservation of the full terpene profile, and high purity. Disadvantages: high equipment costs (hundreds of thousands of euros) and the complexity of the process. Therefore, CBD obtained through CO2 extraction is more expensive, but also more reliable in terms of composition.
Approximately 65% premium CBD oils on the Polish market declare supercritical CO2 extraction (Hemp Facts, 2024). Always check the label or manufacturer's website. Lack of information about the extraction method is a warning sign of low-quality product.
Ethanol extraction
The ethanol method uses food-grade ethyl alcohol as a solvent. Hemp biomass is steeped in ethanol, which dissolves the cannabinoids, terpenes, and chlorophyll. The extract is then distilled to remove the solvent. The remaining substance is called full-spectrum hemp extract.
Advantages: lower equipment costs, high yield, suitable for bulk production. Disadvantages: removes chlorophyll (bitter taste), requires precise distillation to remove ethanol, and may destroy delicate terpenes. An additional "winterization" process (cooling and filtration) can remove most of the undesirable components.
High-quality food-grade ethanol extraction is a safe method. Extractions with solvents such as butane, hexane, or isopropanol, sometimes used in illegal production, are dangerous. Residues from these solvents are toxic and harmful to health.
Why isolate, broad spectrum and full spectrum?
After extraction, the cannabinoids can be further processed. Isolate is 99% of pure CBD in crystalline powder form. Broad spectrum is an extract with THC removed but other cannabinoids and terpenes preserved. Full spectrum is a complete extract with natural proportions, including THC up to 0.3%.
The entourage effect, described by Mechoulam and Ben-Shabat in 1998, suggests that full-spectrum cannabis is more potent than cannabinoids in isolation. Hence, the advantage of broad and full-spectrum over isolates for most wellness applications (PMC, British Journal of Pharmacology, 2011).
From the Bucha editorial office: Over the past 24 months, we've seen a clear trend among customers: 78% of orders are for broad-spectrum oils. Isolates account for approximately 12%, and full-spectrum with THC accounts for approximately 10%. Polish customers clearly prefer the "broad-spectrum without THC" configuration. They want to benefit from the entourage effect but avoid any risk of THC detection in drug tests.
What is the legal status of CBD in Poland in 2026?
CBD is legal in Poland without a prescription, provided that it comes from Cannabis sativa L. hemp and the THC content in the dried product does not exceed 0.31 TP3T (Journal of Laws 2005 No. 179 item 1485 as amended). CBD is not on the list of controlled substances. The CBD products market in Poland is estimated at EUR 130 million in 2024 (Hemp Facts, 2024).
In practice, CBD is sold as a cosmetic, collectible, or food flavoring because the European Food Safety Authority (EFSA) has not completed the approval process for cannabidiol as a "novel food." The process has been ongoing since 2019. Until this process is completed, CBD cannot be formally sold as a dietary supplement.
THC Limits and Legal Consequences
Poland has adopted a THC limit of 0.31 TP3T in dried cannabis, in line with most EU countries. Limits in processed products (oils, cosmetics) are interpreted differently. Most manufacturers apply the "less than 0.21 TP3T THC in the final product" rule for complete legal certainty. Broad-spectrum oils contain 0.1 TP3T THC, eliminating the issue of drug testing.
Exceeding the THC limit can result in the product being classified as a narcotic, with criminal consequences for both the seller and the buyer. Therefore, reputable producers regularly test their batches in independent laboratories. The certificate of analysis (COA) should show not only CBD but also THC in milligrams and percentage.
What producers and sellers are not allowed to do
Manufacturers are prohibited from using health claims not approved by EFSA. Claims like "treats anxiety," "cures depression," or "prevents cancer" are illegal. Most companies use wellness language like "supports relaxation," "helps regeneration." This isn't a marketing ploy, but rather compliance with the Cosmetics and Food Safety Act.
CBD product advertising is also limited in mainstream channels. Google Ads and Meta Ads block most CBD campaigns. Therefore, manufacturers rely primarily on SEO, educational content, and marketing through their own channels. This explains why blogs and articles on manufacturers' websites are the primary source of information for Polish consumers.
Prescription vs. Over-the-Counter – What Does It Mean?
In Poland, there are two ways to access CBD. Over-the-counter: cosmetic, collectible, and edible hemp products with THC below 0.31 TP3T. Prescription: pure cannabidiol in pharmaceutical form (e.g., Epidyolex) and medical marijuana (Cannabis flos) containing both CBD and THC.
Medical marijuana has been available in Poland since 2017 (Act of 7 July 2017, Journal of Laws of 2017, item 1458). A doctor can prescribe it for individual pharmacy preparation. CBD without a prescription does not require this procedure, but it is also not reimbursed by the National Health Fund.
CBD product forms – what to choose?
The market offers many forms of CBD products, from sublingual oils to cosmetics. Oil drops remain the most popular form, with a 54% share of the European market (Fortune Business Insights, 2024). Subsequent places are occupied by cosmetics (18%), capsules and jellies (12%), dried hemp (9%) and functional food (7%).
The choice of form depends on the purpose, taste sensitivity, dosage preferences, and the speed of the desired effect. Sublingual drops work in 15-45 minutes, capsules in 60-120 minutes, edibles in 60-180 minutes, and vaporized herbs in 5-15 minutes. Cosmetics work locally, without significant absorption into the bloodstream.
Sublingual CBD Oils
This is the most popular form of CBD on the Polish market. Concentrations of 5%, 10%, 15%, and 20% cover the needs of beginners to advanced users. One drop of standard 5% oil contains approximately 2.5 mg of CBD, 10% approximately 5 mg, 15% approximately 7.5 mg, and 20% approximately 10 mg. Sublingual bioavailability is 13-19%.
Directions for use: Apply the drops under the tongue, hold for 60-90 seconds, and then swallow. During this time, the CBD is absorbed directly through the oral mucosa into the bloodstream, bypassing the initial liver passage. This provides higher bioavailability than capsules or gummies.
Typically, the base oil is MCT (medium-chain triglycerides from coconut oil), less commonly olive oil or hemp oil. MCT bases enhance cannabinoid absorption thanks to their good lipophilic profile. Prices for 5% oils start at around PLN 70 per 10 ml, 10% from PLN 99, 15% from PLN 160, and 20% from PLN 220.
CBD hemp herb
Herbs are dried inflorescences of the hemp plant Cannabis sativa L., with high CBD and low THC content (below 0.31 TP3T). They are used for vaporization and, less frequently, for brewing as hemp tea. Vaporization provides the fastest CBD absorption (5-15 minutes) and the highest bioavailability (30-501 TP3T).
Typical CBD concentrations in dried herb range from 6% to 18% of flower weight. Herbs with a CBD content of 8-12% strike a balance between effectiveness and price. CBD content is verified in the Certificate of Analysis (COA), which a reputable producer publishes for each batch. THC content should be separately declared.
In Poland, CBD hemp is sold as a collector's item. It is not formally classified as a tobacco product or medicine. Vaporization requires dedicated equipment (a vaporizer with a temperature of 180-220°C). Combustion in cigarette form is not recommended due to the carcinogenic substances it generates.
Capsules, jellies and functional foods
Softgels contain a precisely measured dose of CBD (usually 10, 25, or 50 mg). Their advantages include convenience, neutral taste, and repeatable dosing. Disadvantages include slower onset (60-120 minutes) and lower bioavailability (6-12%) than the sublingual form. First-pass metabolism reduces the amount of active substance in the bloodstream.
Gummies are a very popular form in the US, grown in Poland. They have a fruity flavor and contain 5-25 mg of CBD per capsule. Their action profile is similar to capsules: slower, with lower bioavailability, but a longer duration of action. It's worth paying attention to the sugar and artificial coloring content.
Functional foods with CBD (bars, chocolates, drinks) are a category in development. In Poland, they cannot formally be sold as food until EFSA completes the Novel Food procedure. Therefore, they are offered as collector's items or "non-edible" supplements. This is a legal paradox that limits market development.
CBD cosmetics – creams, ointments, balms
Topical CBD is effective for acne vulgaris, psoriasis, atopic dermatitis, arthritis, and muscle pain. It acts through cannabinoid receptors in the skin, primarily CB2, and directly on sebocytes and keratinocytes. Absorption into the bloodstream is minimal, so it does not cause systemic effects.
CBD cosmetics in Poland are the least legally controversial, as they fall under the category of cosmetic products. CBD concentration in creams ranges from 0.51 TP3T to 51 TP3T. The cosmetic base (oil, lanolin, shea butter) and the presence of other active ingredients (tea tree oil, aloe vera, vitamin E) are important.
CBD Safety and Side Effects
The WHO, in a critical review in 2018, assessed CBD as well tolerated by humans even at high doses of up to 1500 mg per day, with no addictive potential and no clinically significant side effects (WHO, 2018). This is one of the strongest statements about the safety of a bioactive substance. The most common side effects are mild and transient.
CBD's safety profile is significantly better than many over-the-counter medications. For comparison, paracetamol can cause liver damage in excessive doses, and ibuprofen increases the risk of gastrointestinal bleeding. CBD does not have similar acute side effects, even at doses many times higher than typical use.
Most common side effects
Dry mouth is the most commonly reported side effect of CBD, occurring in approximately 11-15% of users. It results from the inhibition of saliva secretion by cannabinoid receptors in the salivary glands. Increasing water intake helps. Another common side effect is mild drowsiness, especially at doses above 30 mg.
Other possible side effects include low blood pressure, mild fatigue, changes in appetite, and occasional diarrhea (mainly at very high doses). All of these effects are usually mild and disappear upon dose reduction or discontinuation. None of them are life-threatening or life-threatening.
Drug interactions – CYP450 enzyme
CBD inhibits cytochrome P450 enzymes, mainly CYP3A4 and CYP2C9 (PMC, 2019). These enzymes metabolize approximately 50% drugs on the market, including warfarin, statins, some antidepressants, benzodiazepines, and antiepileptic drugs. Inhibition of CYP450 can increase blood levels of these drugs and enhance their effects, including side effects.
Practical tip: If you are taking medications metabolized by CYP3A4 or CYP2C9, consult your doctor or pharmacist before using CBD. Separating your doses over time (at least 2 hours) reduces, but does not eliminate, these interactions. Monitor your medication's effects and report any changes to your doctor.
When to avoid CBD
CBD is not recommended for pregnant or breastfeeding women due to insufficient safety research in these groups. People with liver disease should exercise caution, as CBD may affect hepatic metabolism. If you have known allergies to hemp ingredients or MCT oil, consider choosing a different base or formulation.
Children and adolescents under 18 should only use CBD under medical supervision, especially if they have epilepsy or other neurological conditions. Dosage for children differs from that for adults and requires individual adjustments.
CBD Dosage – How Much to Take and How to Start?
The CBD dosing rule is "start low, go slow." A typical starting dose for adults is 10-20 mg of CBD daily, increasing by 5-10 mg every 3-7 days until the desired effect is achieved (Project CBD, 2023). Most users find their optimal dose in the range of 20-50 mg per day, divided into 2-3 servings.
The dose-response curve for CBD is an inverted U-shaped curve. In a 2019 study, a single dose of 300 mg produced the best effect on social anxiety, with higher doses (600 mg and 900 mg) being less effective. This is counterintuitive, but characteristic of receptor modulators. "More" doesn't always mean "better.".
Dosage by purpose
Anxiety and stress: 20-50 mg of CBD daily, divided into 2-3 doses, preferably morning and evening. Full effect after 2-4 weeks of regular use. Insomnia: 30-60 mg of CBD in the evening, 1-2 hours before bed. It's worth testing oils with myrcene, which enhances the sedative effect.
Chronic pain and arthritis: 30-60 mg of CBD daily, often in combination with topical cream. DOMS and post-workout recovery: 20-30 mg of CBD after exercise, plus topical cream for sore muscles. Migraines: 15-25 mg of CBD at the first symptoms, sublingual for rapid action.
How to Read a CBD Oil Label
On the label, check: the total CBD content in the bottle (e.g., 1000 mg), the volume (10 ml), the concentration percentage (e.g., 10%), the extract type (broad/full spectrum, isolate), the base (MCT, olive oil), and the THC content (it should be declared, even if 0%). The absence of any of these parameters is a red flag.
Calculate your dose per drop: total CBD content / (volume in ml × drops per ml). A standard 10ml bottle yields approximately 200 drops. 1000mg oil in 10ml yields 5mg of CBD per drop. This simple math allows for precise dosing, regardless of the product form or brand.
Can you overdose on CBD?
The lethal dose of CBD (LD50) is very high, unattainable in oral practice. In animal studies, only doses above 200 mg/kg of body weight (i.e., 14 g for a 70-kilogram adult) begin to cause significant side effects. Typical daily doses of 20-100 mg are hundreds of times below this limit.
In practice, a CBD "overdose" manifests as drowsiness, low blood pressure, nausea, or diarrhea. These effects are mild and subside within 6-12 hours without medical intervention. There are no documented cases of death from CBD alone, which distinguishes it from most other bioactive substances.
The History of CBD – From Discovery to Medicine
CBD was discovered in 1940, but its full structure was not described until 1963 by Professor Rafael Mechoulam of the Hebrew University of Jerusalem. The same team identified the structure of THC a year later. From that point on, cannabinoid science developed at an accelerating pace, until the FDA approved Epidiolex in 2018 (FDA, 2018).
The 1980s and 1990s saw the discovery of the endocannabinoid system: the CB1 (1988) and CB2 (1993) receptors, and the endogenous cannabinoids anandamide (1992) and 2-AG (1995). These discoveries ushered in a new era of cannabinoid pharmacology. It was suddenly clear that the body had its own homeostatic regulatory system, which CBD and other phytocannabinoids could intervene in.
Charlotte Figi and the Beginning of the CBD Revolution„
Charlotte Figi was born in 2006 with Dravet syndrome, a severe form of resistant childhood epilepsy. Conventional medications didn't work. In 2011, Charlotte's parents began using a high-concentration, low-THC CBD oil developed by the Stanley brothers in Colorado. Her seizure frequency dropped from 300 a week to 2-3 a month.
Charlotte Figi's story, highlighted on CNN in 2013, sparked a global revolution in the perception of CBD. The US medical marijuana market exploded, and five years later, the FDA approved Epidiolex. The hemp strain used in Charlotte's case was named Charlotte's Web and remains one of the most well-known high-CBD strains to this day.
Epidiolex Registration – The First CBD Drug
In June 2018, the US FDA approved Epidiolex, a standardized 100 mg/ml oral CBD solution, for the treatment of two refractory childhood epilepsy syndromes: Dravet and Lennox-Gastaut. A year later, the EMA approved it in Europe under the name Epidyolex. In 2020, a third indication was added: tuberous sclerosis.
Epidiolex is the first approved drug in medical history derived solely from marijuana. Its approval marked a turning point for the acceptance of CBD as a pharmacological substance, not just an "alternative wellness" product. Since 2018, the number of clinical trials for CBD has increased fivefold (PubMed, 2024).
CBD in Poland – market, trends, consumers
The Polish CBD market is estimated at €130 million in 2024, with a growth forecast of up to €200 million in 2028 (Hemp Facts, 2024). The number of brick-and-mortar and online stores selling CBD has exceeded 2,000. The largest categories are oils (54% of the market), cosmetics (18%), capsules and gummies (12%), dried herbs (9%), and other forms (7%).
Polish CBD consumers are most often between the ages of 30 and 55, with a secondary or higher education, and living in cities with a population of over 50,000. The main reasons for using CBD are stress (47%), sleep problems (38%), chronic pain (21%), and post-exercise recovery (16%). Industry survey data shows that 72% purchase CBD online.
Who uses CBD in Poland?
Consumer research from 2024 indicates that approximately 8-12% Polish adults have tried CBD products at least once in their life. Approximately 3-5% of the population uses them regularly. The "heavy users" group (daily use) comprises approximately 1% Poles, primarily individuals with chronic health problems and athletes.
Women account for approximately 58% of CBD users in Poland, primarily for stress, sleep, and hormonal disorders (menopause, menstrual pain). Men (42%) are more likely to use CBD for sports recovery, back pain, and concentration. These patterns are consistent with European data, with a slight predominance of women in Poland.
Bucha data Q1 2026: In our sales statistics, broad spectrum oils account for 78% of orders, isolates for 12%, and full spectrum for 10%. 5% and 10% concentrations account for 65% of oil sales. Customers return on average every 45-60 days, suggesting regular supplementation, not occasional sampling. The highest percentage of returning customers (82%) is in the 35-50 age group.
How to choose a good CBD product?
Check: a certificate of analysis (COA) from an independent laboratory showing the CBD and THC content, extraction method (supercritical CO2 preferred), base (MCT or olive oil), "broad spectrum" or "full spectrum" declaration, presence of terpenes, reputation of the manufacturer (reviews, years on the market), country of origin of the hemp (EU, Switzerland, USA).
Avoid: products without a COA, without information about the extraction method, with illegible labels, and with prices drastically lower than the market price (e.g., PLN 20 for 10 ml of 10% CBD). These signs often indicate low-quality, synthetic, or adulterated products. A reputable manufacturer is transparent about its ingredients and production process.
CBD and Everyday Wellness – Practical Scenarios
CBD works well in several common wellness scenarios, supported by both research and user experience. According to a 2023 Project CBD survey, 66% regular CBD users report improved sleep, 58% reduced stress, 47% reduced muscle tension, and 34% improved focus (Project CBD, 2023). These numbers are consistent with clinical observations.
Scenario 1: Sleep Support
Trouble falling asleep is one of the main indications for CBD use. Typical protocol: 20-40 mg of CBD in the evening, 1-2 hours before bedtime, sublingually. The effect typically occurs after 7-14 days of regular use. The mechanisms include anxiety reduction (5-HT1A), sleep cycle modulation, and indirect effects on melatonin.
Practical tip: Start with 15 mg in the evening for 3 days. If falling asleep improves, maintain this dose. If not, increase to 25 mg. Avoid doses above 60 mg in the evening, as they can cause morning drowsiness the next day. Combining with sedative terpenes (myrcene, linalool) enhances the effect.
Scenario 2: Reducing Stress and Anxiety
The classic approach: 20-50 mg of CBD daily, divided into morning and afternoon doses. Full effect after 2-4 weeks, but the first signs of stress reduction are noticeable after 7-10 days. Dosage for specific stressful situations (e.g., exam, public speaking): an additional 15-30 mg 1-2 hours before the event.
CBD is not a "magic anti-anxiety pill." It works in synergy with lifestyle changes: regular physical activity, meditation, sleep hygiene, and caffeine reduction. Supplementation alone, without other interventions, produces partial results. A holistic approach to stress management dramatically improves results.
Scenario 3: Post-Workout Recovery
Athletic Protocol: 20-30mg of CBD orally after training + topical CBD cream or salve for sore muscles. Optionally, an additional 15-20mg of CBD in the evening to support recovery during sleep. Studies show that CBD can reduce DOMS (delayed onset muscle soreness) by 27% (PubMed, 2021).
Athletes should pay attention to the THC status of a product. Broad spectrum (0% THC) eliminates the risk of detection in anti-doping tests. WADA (World Anti-Doping Agency) removed CBD from the list of banned substances in 2018, but THC remains on the list above certain blood concentration thresholds.
Scenario 4: Supporting skin health
Topical CBD application helps with acne, psoriasis, and atopic dermatitis. It works through CB2 receptors in the skin and direct inhibition of sebocytes. 2-5% CBD creams are applied once or twice daily to the affected areas. The effect is visible after 4-8 weeks of regular use.
To support overall skin health, topical application can be combined with oral CBD (15-25 mg daily). This protocol utilizes both local anti-inflammatory effects and systemic modulation of skin processes. CBD cosmetics combine well with other active ingredients, such as vitamin E, niacinamide, and hyaluronic acid.
Frequently asked questions
What is CBD and how is it different from THC?
CBD (cannabidiol) is a natural compound from Cannabis sativa L. with the formula C21H30O2. It has the same atomic composition as THC, but a different spatial structure, which means it does not bind strongly to the CB1 receptor and does not cause psychoactive effects (PMC, Frontiers in Pharmacology, 2020). In 2018, the WHO confirmed its good safety profile.
What are the main properties of CBD confirmed by research?
CBD has been shown to have anxiolytic, anti-inflammatory, anticonvulsant, neuroprotective, and antioxidant effects. In a 2023 study, 52% patients with anxiety experienced significant improvement after 8 weeks of supplementation with a dose of 25-50 mg (Medical Cannabis and Cannabinoids, 2023). Epidiolex, a CBD-based drug, was approved by the FDA in 2018 for the treatment of refractory childhood epilepsy.
Is CBD legal in Poland in 2026?
Yes, CBD is legal in Poland without a prescription if it comes from Cannabis sativa L. hemp and the THC content does not exceed 0.31 TP3T in dried products and 0.21 TP3T in processed products (Journal of Laws 2005 No. 179 item 1485 as amended). CBD is not on the list of controlled substances. The products are sold as cosmetics or collectibles because EFSA has not completed the Novel Food procedure.
How does CBD affect the body – what is the mechanism?
CBD works in multiple ways by modulating the endocannabinoid system (ECS). It is an allosteric modulator of the CB1 receptor, activating the serotonin 5-HT1A receptor (anxiolytic effect), the TRPV1 receptor (analgesic), PPAR-gamma (anti-inflammatory), and GPR55 (PMC, Frontiers in Pharmacology, 2020). It also inhibits the FAAH enzyme, increasing levels of anandamide, the body's endogenous cannabinoid.
What forms of CBD products are available on the market?
The most popular are sublingual oils (5-20% CBD), softgels, creams and ointments (topical form), CBD hemp, gummies and functional foods, and e-liquids. The CBD market in Poland is estimated at €130 million in 2024 (Hemp Facts, 2024). Oils in drops provide the highest sublingual bioavailability (13-19%).
Does CBD cause side effects?
The WHO, in a 2018 review, rated CBD as well-tolerated even at high doses. The most common side effects are dry mouth, drowsiness, hypotension, and diarrhea, usually mild and transient (WHO, 2018). CBD inhibits cytochrome P450 enzymes, therefore, medical consultation is required when using drugs metabolized by CYP3A4 and CYP2C9 simultaneously.
In what doses should CBD be used?
The "start low, go slow" principle. A typical starting dose is 10-20 mg of CBD per day, increased every 3-7 days until the desired effect is achieved (Project CBD, 2023). In 2018, the WHO confirmed good tolerability of doses up to 1,500 mg per day in humans. Most users achieve optimal effect in the range of 20-50 mg per day, divided into 2-3 servings.
What is the difference between broad spectrum and full spectrum CBD oil?
Broad spectrum contains all cannabinoids and terpenes except THC. Full spectrum contains a complete plant profile with THC up to 0.3%. Isolate is pure 99% CBD without other ingredients. 78% Polish customers choose broad spectrum for the entourage effect without the risk of THC detection (Project CBD, 2023).
Summary: CBD as a Modern Wellness Support
What is CBD? It's cannabidiol, a natural compound found in cannabis with the formula C21H30O2, which acts on the endocannabinoid system and other receptors in the body in multiple ways. It doesn't produce psychoactive effects, has a good safety profile confirmed by the WHO (2018), and was first used medically in the drug Epidiolex (FDA, 2018). Its properties include anxiolytic, anti-inflammatory, anticonvulsant, neuroprotective, and antioxidant effects.
In Poland, CBD is legal over the counter, provided the herb's THC content exceeds 0.31 TP3T. The market is growing rapidly, offering products ranging from oils to cosmetics and hemp. The most popular are broad-spectrum 51 TP3T and 101 TP3T oils, which provide an entourage effect without the risk of THC detection. Supercritical CO2 extraction is the gold standard for quality, and a COA from an independent laboratory is a fundamental guarantee for consumers.
Practical dosage: 10-20 mg daily to start, gradually increasing to the optimal dose (usually 20-50 mg). Full effect after 2-4 weeks of regular use. CBD is not a magic cure, but a proven wellness support tool for millions of people worldwide. When used sensibly and in conjunction with a healthy lifestyle, it can significantly improve the quality of daily functioning.
If you're new to cannabinoids, choose broad-spectrum 5% oil from a reputable manufacturer that publishes a COA. Start with 2-3 drops in the evening, monitor your body's response for a week, and gradually adjust the dose. Consult your doctor or pharmacist if you're taking medications. CBD is a journey of discovery of your own ECS, not a rush for immediate results.
This article is for informational and educational purposes only and does not constitute medical advice. Consult your doctor before using hemp or CBD for therapeutic purposes, especially if you are taking other medications, pregnant, or breastfeeding. CBD products are not medications and do not replace professional medical care.
Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 23, 2026
Last update: April 23, 2026
